Lanean...
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
Combining immunotherapy with targeted therapy blocking oncogenic BRAF(V600) may result in improved treatments for advanced melanoma. Here, we developed a BRAF(V600E)-driven murine model of melanoma, SM1, which is syngeneic to fully immunocompetent mice. SM1 cells exposed to the BRAF inhibitor vemura...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3422880/ https://ncbi.nlm.nih.gov/pubmed/22693252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-2837 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|